Compare UiPath Inc (PATH) vs Roivant Sciences Ltd. Common Shares (ROIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
UiPath Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? UiPath Inc trades at $13.26 (market cap $6.81B), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 3.7× UiPath Inc's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, UiPath Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold UiPath Inc for 139 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| PATH | ROIV | |
|---|---|---|
Market Cap | $6.81B | $25.09B |
Volume | 22,766,109 | 5,738,571 |
Sector | Technology | Health |
52-Week High | $19.29 | $41.81 |
52-Week Low | $9.38 | $16.04 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $5.61B | $21.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
UiPath (PATH) trades at $13.25, up 1.15% with mixed technical signals showing bearish momentum but neutral oscillators. The company demonstrates improving fundamentals with revenue growing from $1.43B in 2025 to projected $1.7B in 2026, while transitioning from net losses to profitability. Recent partnerships with Snowflake and BDO highlight strategic positioning in AI automation, though the stock faces near-term headwinds from valuation concerns and competitive pressures.
PATH presents a turnaround story with strong revenue growth and path to profitability, but faces execution risks amid competitive automation landscape. The consensus price target of $15.13 suggests 14% upside potential, though technical weakness and mixed analyst sentiment warrant caution. Key catalysts include AI platform adoption and enterprise expansion, while risks involve growth sustainability and margin pressures.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Read more on PATH →About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →
